The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination
with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin
has been shown to have fewer side effects in the control of blood glucose values.
Obesity and diabetes are states of increased inflammation and can influence the free radicals
and inflammatory markers (chemicals in the blood which increase due to inflammation in the
body) and are also major risk factors for atherosclerotic disease. In this study we want to
see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an
anti-inflammatory effect in the human. The purpose of this study is to determine if the
addition of sitagliptin to diabetic patients will provide added benefit. We believe that
sitagliptin provides these added benefits by suppressing free radicals (charged substances
that cause damage to the body) and inflammation.